Drugs / BC008-1A
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06773507 | May 2025 → Jun 2026 overdue | esophageal squamous cell carcinoma, non-small cell lung carcinoma | Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT06773481 | Apr 2025 → Jun 2026 overdue | glioblastoma | Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BC008-1A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06773507 ↗ |
| Action | Inhibit | “BC008-1A targets PD-1 and TIGIT to block the relevant signaling pathways” NCT06773481 ↗ |
| Route | Intravenous | “900 mg BC008-1A will be intravenously injected once every 3 weeks” NCT06773481 ↗ |